Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Change in Accured Expenses (2018 - 2026)

DiaMedica Therapeutics filings provide 9 years of Change in Accured Expenses readings, the most recent being -$1.2 million for Q1 2026.

  • Quarterly Change in Accured Expenses rose 6.46% to -$1.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$807000.0 through Mar 2026, down 169.87% year-over-year, with the annual reading at -$892000.0 for FY2025, 135.84% down from the prior year.
  • Change in Accured Expenses hit -$1.2 million in Q1 2026 for DiaMedica Therapeutics, down from $282000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $1.3 million in Q4 2024 and bottomed at -$1.3 million in Q1 2025.
  • Average Change in Accured Expenses over 5 years is $63588.2, with a median of $38000.0 recorded in 2023.
  • The largest annual shift saw Change in Accured Expenses surged 936.84% in 2024 before it plummeted 7021.05% in 2025.
  • DiaMedica Therapeutics' Change in Accured Expenses stood at $737000.0 in 2022, then fell by 28.09% to $530000.0 in 2023, then soared by 145.47% to $1.3 million in 2024, then tumbled by 78.32% to $282000.0 in 2025, then plummeted by 536.17% to -$1.2 million in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Change in Accured Expenses are -$1.2 million (Q1 2026), $282000.0 (Q4 2025), and $469000.0 (Q3 2025).